|Articles|January 1, 2005

CLINICAL TIP: Go down, capsules!

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

Contemporary Pediatrics week in review: August 24-28, 2026 | Image Credit: © Artur - stock.adobe.com.

Contemporary Pediatrics week in review: August 24-28, 2026

ByContemporary Pediatrics Staff

August 28th 2026

Longer treatment may yield continued improvement in pediatric anxiety

Longer treatment may yield continued improvement in pediatric anxiety

ByBradley Peterson, MD

August 28th 2026

FAQ: What does the new AAP iron deficiency guidance mean for your practice? | Image Credit: ©Elena - stock.adobe.com.

FAQ: What does the new AAP iron deficiency guidance mean for your practice?

ByContemporary Pediatrics Staff

August 28th 2026

CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak | Image Credit: © Tada Images - stock.adobe.com.

CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak

ByMorgan Ebert, Executive Editor

August 27th 2026

Treatment choice for pediatric anxiety may depend on preference and access

Treatment choice for pediatric anxiety may depend on preference and access

ByBradley Peterson, MD

August 27th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

New multisociety position paper details hospital strategies to close gaps in sepsis care

CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak

Contemporary Pediatrics week in review: August 24-28, 2026

Longer treatment may yield continued improvement in pediatric anxiety

Lebrikizumab phase 3 data show improvements in atopic dermatitis symptoms, itch in children